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have failed PBSC mobilization is high. Auto-BMT should not be
routinely recommended to pts who have failed PBSC mobilization.
Alternative strategies, including reduced intensity or non-myeloa-
blative allogeneic transplants should be considered in this patient
group.
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AN AUDITED RETROSPECTIVE ANALYSIS OF CORD BLOOD TRANS-
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Limited cell dose has hampered widespread use of CBT. The red
cell depletion (RD) techniques that are widely used incur signiﬁ-
cant nucleated cell loss after processing; therefore, to minimize cell
loss and still reduce volume during processing, a technique was
devised to deplete plasma (PD) but not red blood cells. An updated
retrospective audited analysis of 230 consecutive patients with
engraftment and/or survival data from 81 transplant centers over 5
continents up to September 2006 was performed. The data was
audited in three ways: (1) by CIBMTR using on-site audits for
40% of the PD CBT with available outcome data, (2) by NMDP
for PD CBT that it faciliates, (3) and by the transplant center
working with the cord blood bank. Patient characteristics: median
age 7.9 yo, range 0.3-63, 66 16 yo (29%); median weight 27 kg,
range 4.8-137, 70,50kg (31%); male 59%; median # HLA ABDR
matches 4.0; median pre-freeze TNC dose 5.6  107/kg (n230);
transplant center reported median post-thaw TNC dose 3.9 
107/kg (n219); median pre-freeze CD34 dose 1.8  105/kg;
malignant indications 69%; transplants outside U.S. 37%; double
cord transplant 25%; and non-myeloablative 19%. Of the malig-
nant cases, 40 (26%) had standard risks, 91 (59%) had advanced
risks, and 24 (15%) with unknown status. For all engrafted pa-
tients, the median time to engraftment for ANC 500, platelet 20K
and 50K were 22 days (range 6-69), 48 days (range 12-186), and 62
days (range 21-374) respectively. Kaplan-Meier estimates of en-
graftment of ANC500, platelet 20K and 50K engraftment were
892% (n215), 784% (n196) and 754% (n195) respec-
tively. The incidence of grade III-IV acute GVHD and extensive
chronic GVHD were 13% and 12% respectively. One-year relapse
rate was 254% for all patients (n223), and TRM was 193%
and 293% (n228) at 100 days and 1 year. With a median
follow-up of 258 days (range 2-1741 days) for the surviving pa-
tients, the Kaplan-Meier estimates of 1-year OS (n228) and DFS
(n223) are 583% and 563% respectively. To our knowledge,
this is one of few studies originated by cord blood banks that was
extensively audited by external data and transplant registries. Other
unique aspects were the very high mean and median cell dose as
well as the minority and international focus of the patients. These
results conﬁrm our earlier ﬁndings and demonstrate that CBT
using PD CB can achieve outstanding engraftment and survival.
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We present preliminary data of haploidentical transplant for 13
patients (pts) with acute leukemia using a chemotherapy-only pre-
parative regimen of Melphalan 140 mg/m2 on day –8; Thiotepa 10
mg/kg on day –7; Fludarabine 40 mg/m2 on days –6, -5, -4, -3; 1.5
mg/kg of rabbit ATG/day days –6, -5, -4, -3.aˆ device as a means of
T-cell depletion. All products had 1  104 CD3 T-cells/kg
recipient body weight and needed a minimum of 5  106 CD34
cells/kg but preferably 1  107 CD34 cells/kg recipient body
weight. Age ranged 23-50 years/median 37 years, four patients
were in advanced remission and nine were in refractory relapse.
Patients received intensive PCP prophylaxis with sulfamethox-
azole-trimethoprim and pentamidine prior to transplant and dur-
ing pancytopenia; CMV prophylaxis with valganciclovir during the
BMT prep and foscarnet® while pancytopenic; and with liposomal
amphotericin or cancidas for fungal prophylaxis.
Two patients had primary graft failure-one survived disease free
and one relapsed. One patient died of multiple organ failure prior
to engraftment. Median time to engraftment was 15 days (range,
9-26) to 500 neutrophils and 14 days to platelets 20,000 (range,
13-25).
Seven patients died of relapse at a median of 10 months (range
2-13 months), and one patient died of a viral infection. Two of 10
patients who engrafted developed grade one acute graft-versus-
host (GVHD) and four patients had chronic GVHD (3 limited, 1
extensive). Four patients survive beyond 2 years, without recurrent
disease.
This report for haploidentical transplant demonstrates that a
chemotherapy only preparative regimen can achieve a high rate of
engraftment. Infectious complications were minimal with aggres-
sive prophylaxis. Long-term remission are achievable with little
risk of severe GVHD with t-cell depletion with use of CliniMACSaˆ
in haploidentical stem cell transplant.
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Background: Autologous BMT has been abandoned in favor of
PBSC collected after G-CSF with or without chemotherapy.
PBPC autografts with low CD34 cell content provide late neu-
trophil and inadequate platelet and red cell reconstitution. Repeat
mobilization and bone marrow harvest are possible ways to cir-
cumvent this problem. No studies address minimum cell contents
for combined PBPC/BM grafts and transplant outcomes using
combined grafts in the context of previous inadequate PBSC col-
lection. Methods: Retrospective analysis of 19 autologous trans-
plants performed with a combined PBPC/BM graft for poor initial
PBPC collection. Mobilization was ﬁlgrastim 10 g/kg/day with-
out chemotherapy x 5 days or after CY, ICE or RICE to peripheral
CD34 count  10/L and until completion of collection. A
standard BM harvest (max 20 mL/kg) was done if collection con-
tained  2.5  106 CD34 / kg. Results: Patients median age was
55 (19-74). Diagnoses: MM (7), NHL (7), HL (4) and AML (1).
Cell contents of the combined grafts were (CD34 / kg x 106
median  standard deviation (range)) for BM 1.1 0.6 (0.3-2.7)
PBPC 1.2  0.7 (0.04-2.8) Infused: 2.2  1.1 (1.4-4.7). Eight
combined grafts contained  2.0  106 CD34 / kg (1.3-1.8).
Engraftment in days as median (range) was: ANC500: 11 (9-39) Plt
20,000: 25 (15-59) RBC independence: 28 (0-58). Six patients died
of progressive disease (58-293 days post-ASCT). One patient died
of infection day 141 and one of MI day 11. All patients maintained
an ANC 1,000 without growth factor support beyond day 19 but
one who required intermittent growth factor support until day 39.
One patient experienced delayed graft failure (platelets  10,000)
on day 90 at concomitantly with acute cholecystitis. The CD34 /
kg content of the PBPC collection alone did not predict that of the
BM harvest but it correlated with time to ANC500 (r  -0.46 p 
0.046) and time to Plt 20,000 (r  -0.54 p  0.037). Neither the
BM nor the total infused CD34 / kg content or the BM TNC/kg
content correlated with engraftment or outcomes. In particular,
patients above or below 2.0  106 CD34/kg had similar kinetics
of engraftment and overall mortality. Conclusions: BM harvest
after failed PBPC collection is a reliable option to obtain an
adequate combined autograft. Combined BM/PBSC grafts can
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